Key result
Tirofiban administered after direct thrombectomy increased the rate of favorable functional outcomes at 90 days compared to thrombectomy alone in patients with acute ischemic stroke.
Why the study?
Although tirofiban and endovascular thrombectomy are widely used in acute ischemic stroke, the effectiveness of their combined application remains debated.
Does tirofiban improve functional outcomes in patients with acute ischemic stroke undergoing direct thrombectomy for anterior circulation occlusion?
Cohort (n=204)
Yes
Does tirofiban improve functional outcomes in patients with acute ischemic stroke undergoing direct thrombectomy for anterior circulation occlusion?
Tirofiban administered after direct endovascular thrombectomy for acute ischemic stroke with anterior circulation occlusion significantly improved 90-day functional independence without increasing the risk of symptomatic intracerebral hemorrhage.
Answers are grounded in this paper and cite their sources.
Tirofiban may improve outcomes after direct thrombectomy; hypothesis-generating and leaves open need for randomized confirmation.
OBJECTIVE: Although tirofiban and endovascular thrombectomy have been widely used in the treatment of acute ischemic stroke (AIS) patients, the effectiveness of their combined application remains a subject of debate. This study aimed to assess the efficacy and safety of tirofiban in direct thrombectomy for AIS with anterior circulation vessel occlusion. METHODS: A total of 204 patients undergoing direct thrombectomy between January 2020 and December 2021 for AIS with anterior circulation vessel occlusion from four hospitals were included in this study. Patients at high risk of reocclusion with severe atherosclerosis, those who achieved successful recanalization for ≥ 3 stent retriever passes, or those who underwent emergency stenting or balloon angioplasty for severe residual stenosis were treated with tirofiban. Following a low-dose intra-arterial bolus (0.25-1 mg) immediately after endovascular treatment, tirofiban was administered continuously through intravenous infusion (0.1 μg/kg/min) for 12-24 hours. The primary efficacy outcome was evaluated using the 90-day modified Rankin Scale score. The safety outcome was assessed using symptomatic intracerebral hemorrhage (sICH) and mortality rates. RESULTS: The tirofiban group and nontirofiban group each included 102 patients. The favorable outcome rate in the tirofiban group was significantly higher than that in the nontirofiban group (53.9% vs 35.3%, p = 0.007). However, the sICH and 90-day mortality rates were lower in the tirofiban group, despite a lack of statistical significance (sICH: 15.7% vs 16.7%, p = 0.849; 90-day mortality: 16.67% vs 24.51%, p = 0.166). Finally, it was found that older patients (> 72 years), male patients, patients with admission National Institutes of Health Stroke Scale scores > 14, patients with a time from onset to reperfusion > 327 minutes, and patients with a medical history of diabetes tend to benefit from tirofiban treatment. CONCLUSIONS: This study suggests that tirofiban combined with direct thrombectomy improves functional outcomes of AIS and reduces the 90-day mortality rate. Therefore, it could be considered as a suitable treatment option for AIS patients with anterior circulation vessel occlusion.
No takes yet. Share an insight, caveat, or question.
Guan et al. (2023) conducted a cohort in Acute ischemic stroke with anterior circulation vessel occlusion (n=204). Tirofiban vs. No tirofiban (direct thrombectomy alone) was evaluated on Favorable functional outcome at 90 days (modified Rankin Scale score of 0-2) (adjusted OR 0.429, 95% CI 0.207-0.888, p=0.023). Tirofiban administered after direct thrombectomy increased the rate of favorable functional outcomes at 90 days compared to thrombectomy alone in patients with acute ischemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: